A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain

American Journal of Gastroenterology

Volumn 110, Issue 5, 2015, Pages 725-732

  Jamal, M Mazen ^a,b   Adams, Atoya B ^c   Jansen, Jan Peter ^d   Webster, Lynn R ^e  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Impact Clinical Trials   (United States)

^d Schmerzzentrum Berlin   (Germany)

^e PRA HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCODONE; LUBIPROSTONE; OPIATE; OXYCODONE; PARACETAMOL; PLACEBO; CHLORIDE CHANNEL STIMULATING AGENT; NARCOTIC ANALGESIC AGENT; PROSTAGLANDIN E1;

ABDOMINAL PAIN; ADULT; ARTICLE; CHRONIC PAIN; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NAUSEA; OPIOID INDUCED CONSTIPATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT DURATION; VOMITING; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; DEFECATION; MIDDLE AGED; MULTICENTER STUDY; TIME FACTOR;

ADULT; ALPROSTADIL; ANALGESICS, OPIOID; CHLORIDE CHANNEL AGONISTS; CHRONIC PAIN; CONSTIPATION; DEFECATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LUBIPROSTONE; MALE; MIDDLE AGED; QUALITY OF LIFE; TIME FACTORS;

EID: 84928928194     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2015.106     Document Type: Article

References (31)

1. Chou R, Fanciullo GJ, Fine PG et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009 ; 10 : 113-30.
2. Kalso E, Allan L, Dellemijn PL et al. Recommendations for using opioids in chronic non-cancer pain. Eur J Pain 2003 ; 7 : 381-6.
3. Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther 2005 ; 7 : R1046-51.
4. Bell TJ, Panchal SJ, Miaskowski C et al. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med 2009 ; 10 : 35-42.
5. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003 ; 63 : 649-71.
6. Rachinger-Adam B, Conzen P, Azad SC. Pharmacology of peripheral opioid receptors. Curr Opin Anaesthesiol 2011 ; 24 : 408-13.
7. Benyamin R, Trescot AM, Datta S et al. Opioid complications and side effects. Pain Physician 2008 ; 11 : S105-20.
8. Lacy BE, Levy LC. Lubiprostone: a chloride channel activator. J Clin Gastroenterol 2007 ; 41 : 345-51.
9. Sun X, Wang X, Wang GD et al. Lubiprostone reverses the inhibitory action of morphine on mucosal secretion in human small intestine. Dig Dis Sci 2011 ; 56 : 330-8.
10. Amitiza? (lubiprostone). Sucampo Pharma Americas Inc.: Bethesda, MD and Takeda Pharmaceuticals America Inc.: Deerfield, IL 2013.
11. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guideline for Good Clinical Practice E6(R1) http://www.ich.org/Accessed 11 December 2012.
12. Marquis P, De La Loge C, Dubois D et al. Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Scand J Gastroenterol 2005 ; 40 : 540-51.
13. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001 ; 33 : 337-43.
14. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958 ; 53 : 457-81.
15. Hommel G. A stagewise rejective multiple test procedure based on a modified Bonferroni test. Biometrika 1988 ; 75 : 383-6.
16. Barish CF, Drossman D, Johanson JF et al. Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci 2010 ; 55 : 1090-7.
17. Johanson JF, Morton D, Geenen J et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 2008 ; 103 : 170-7.
18. Wong BS, Camilleri M. Lubiprostone for the treatment of opioid-induced bowel dysfunction. Expert Opin Pharmacother 2011 ; 12 : 983-90.
19. Ford AC, Brenner DM, Schoenfeld PS. Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis. Am J Gastroenterol 2013 ; 108 : 1566-74. quiz 75.
20. Relistor (methylnaltrexone bromide). Salix Pharmaceuticals Inc.: Raleigh, NC 2013.
21. AstraZeneca. FDA approves MOVANTIK™ (naloxegol) Tablets C-II for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain 2014.
22. Michna E, Blonsky ER, Schulman S et al. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain 2011 ; 12 : 554-62.
23. Holzer P. Non-analgesic effects of opioids: management of opioid-induced constipation by peripheral opioid receptor antagonists: prevention or withdrawal? Curr Pharm Des 2012 ; 18 : 6010-20.
24. L?enstein O, Leyendecker P, Lux EA et al. Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials. BMC Clin Pharmacol 2010 ; 10 : 12.
25. Entereg (alvimopan). Cubist Pharmaceuticals Inc.: Lexington, MA 2013.
26. Linzess (linaclotide). Forest Laboratories Inc.: St. Louis, MO and Ironwood Pharmaceuticals Inc.: Cambridge, MA 2013.
27. Sloots CE, Rykx A, Cools M et al. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig Dis Sci 2010 ; 55 : 2912-21.
28. Cuppoletti J, Chakrabarti J, Tewari K et al. Methadone but not morphine inhibits lubiprostone-stimulated Cl(-) currents in T84 intestinal cells and recombinant human ClC-2, but not CFTR Cl(-) currents. Cell Biochem Biophys 2013 ; 66 : 53-63.
29. Spierings E, Joswick T, Lindner E et al. Long-Term Safety And Efficacy Of Lubiprostone In Opioid-Induced Bowel Dysfunction In Patients With Chronic, Non-Cancer Pain: Results Of A Phase 3, Open-Label Clinical Trial American College of Gastroenterology : Las Vegas, NV, 2012.
30. Lembo AJ, Johanson JF, Parkman HP et al. Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation. Dig Dis Sci 2011 ; 56 : 2639-45.
31. Chey WD, Drossman DA, Johanson JF et al. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2012 ; 35 : 587-99.